As a result of the March 9, 2009 reversal of the 2001 restrictions on federal funding of human embryonic stem cell research, suppliers of stem cell related products are in need of a fast, accurate assessment of new opportunities in the stem cell products market. Additionally, given that practical stem cell-based therapies can take years to develop, suppliers will benefit from a clear understanding of the wide range of products that support basic stem cell research already in progress. Capitalizing on New Opportunities for Stem Cell Products, BioInformatics LLC’s latest report, will enable suppliers to respond quickly to a market disrupted by an Executive Order, and to gain a better understanding of how today’s stem cell products market is driven by long-term stem cell research requirements.
In Capitalizing on New Opportunities for Stem Cell Products, we surveyed close to 500 scientists from around the world about their current—and planned—areas of research, usage of stem cell products and preferred suppliers. This report will help you to determine areas poised for growth (i.e., media, sera, supplements and cell lines) in the stem cell research products market, identify potential key competitors (including percentage of products purchased from each major supplier), and plan a long-term strategy to secure your leading position in this expanding market. For tactical planning purposes, the report includes detailed market share estimates across major stem cell product categories by market segment, geographic region and top suppliers. Combined with data on scientists’ stem cell research budgets and expected changes in spending through 2011, suppliers can use this information to anticipate areas of growth and product saturation.
One key finding in this report was that only 14% of the scientists surveyed indicated that the lifting of the restrictions on federal funding for human embryonic stem cell research will affect their decision as to what types of stem cells to use in their research; the majority of study will still involve using adult stem cells, suggesting that these cells will continue to play a major role in advancing the field of stem cell research. Furthermore, almost half of the scientists indicated that the goal of their research is understanding basic biology of stem cells, as opposed to developing cell-based therapies, drug discovery or preclinical/clinical trials. More specifically, we have found that 75% of respondents are focused on stem cell differentiation, which has tremendous implications for product development. (Please see page 2 for supporting data.)
This analysis also provides suppliers with critical insight into optimizing product offerings based upon scientists’ level of satisfaction with stem cell culture products and the level of interest in developing integrated stem cell product lines and services. The scientists surveyed share their opinions on what new product/technologies would be most beneficial to their research. Additionally, the report reveals what channels stem cell scientists use to access information relevant to their research, which in turn can be used by suppliers to more effectively target their products and services.
The March 2009 policy change will have implications for life science suppliers as academic scientists consider conducting research on previously unavailable human embryonic stem celllines. But while the excitement about human embryonic stem cell research is on the rise, including in the pharmaceutical and biotech industry, suppliers need actionable information about scientists’ plans to pursue research using all types of cell lines in a global market. This report provides insights into the origins and sources of stem cells currently used in the lab (adult, embryonic and induced pluripotent) and those likely to be used over the next several years—in addition to differentiated cell types and associated diseases under investigation—allowing suppliers to anticipate the types of stem cell culture products scientists will need to purchase. Moreover, this report includes a supplemental section about scientists who plan to conduct stem cell research in the near future to help companies better anticipate the stem cell product needs of new customers.
Capitalizing on New Opportunities for Stem Cell Products provides a roadmap for stem cell product suppliers to help navigate a landscape that is poised for change—and growth. This analysis was designed to guide suppliers in redirecting resources to new areas and markets, and to help refine current offerings by making them more responsive to scientists who are already engaged in stem cell research.
(0 items)
